Patent · US Active

Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

US10738075B2 · kind B2 · utility

0Cited by

14References

9Claims

0Family size

Assignee

Evestra, Inc. · US

Inventors

Hareesh Nair · San Antonio, US
Bindu Santhamma · San Antonio, US
Klaus Nickisch · Berlin, DE

Key dates

Filing date	Jul 18, 2018
Grant date	Aug 11, 2020
Priority date	—
Expiry date	Jul 18, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07J71/001
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.